Literature DB >> 6546943

Antigenic modulation induced by monoclonal antibodies: antibodies to measles virus hemagglutinin alters expression of other viral polypeptides in infected cells.

R S Fujinami, E Norrby, M B Oldstone.   

Abstract

Polyclonal antibody to measles virus can have profound effects on external (outer plasma membrane) as well as internal (cytoplasmic) viral polypeptides expressed in infected cells. The process, termed "antibody-induced antigenic modulation," was further investigated by using monoclonal antibody to several viral polypeptides. Four monoclonal antibodies against the viral hemagglutinin had the ability to decrease the expression of the phosphoprotein, fusion, and membrane protein. A monoclonal antibody to the nucleocapsid protein did not cause these changes. The observed decreases were not due to preferential degradation of viral polypeptides as determined by pulse-chase experiments. Our results indicate that a specific signal to an epitope on the plasma membrane (monoclonal antibody measles virus hemagglutinin) can alter the expression of measles virus phosphoprotein and membrane protein, both polypeptides present in the cytoplasm of infected cells.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6546943

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Neutralizing anti-gH antibody of Varicella-zoster virus modulates distribution of gH and induces gene regulation, mimicking latency.

Authors:  Kimiyasu Shiraki; Tohru Daikoku; Masaya Takemoto; Yoshihiro Yoshida; Kazuhiro Suzuki; Yasushi Akahori; Toshiomi Okuno; Yoshikazu Kurosawa; Yoshizo Asano
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Modulation of immune system function by measles virus infection: role of soluble factor and direct infection.

Authors:  R S Fujinami; X Sun; J M Howell; J C Jenkin; J B Burns
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

3.  Prolonged persistence of measles virus RNA is characteristic of primary infection dynamics.

Authors:  Wen-Hsuan W Lin; Roger D Kouyos; Robert J Adams; Bryan T Grenfell; Diane E Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-07       Impact factor: 11.205

Review 4.  Monoclonal antibodies: implications for virology. Brief review.

Authors:  K C McCullough
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

5.  Interaction of Immunoglobulin with Cytomegalovirus-Infected Cells.

Authors:  Nobuyasu Aiba; Atsuko Shiraki; Misako Yajima; Yukari Oyama; Yoshihiro Yoshida; Ayumu Ohno; Hiroshi Yamada; Masaya Takemoto; Tohru Daikoku; Kimiyasu Shiraki
Journal:  Viral Immunol       Date:  2017-06-09       Impact factor: 2.257

6.  A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro.

Authors:  K Mozdzanowska; M Furchner; G Washko; J Mozdzanowski; W Gerhard
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

7.  Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein.

Authors:  Masahiro Kajihara; Andrea Marzi; Eri Nakayama; Takeshi Noda; Makoto Kuroda; Rashid Manzoor; Keita Matsuno; Heinz Feldmann; Reiko Yoshida; Yoshihiro Kawaoka; Ayato Takada
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

8.  Antibodies to varicella-zoster virus modulate antigen distribution but fail to induce viral persistence in vitro.

Authors:  C Sadzot-Delvaux; P Marc; L Lebon; M P Merville-Louis; J Piette; B Rentier
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

9.  Adaptive immune response to viral infections in the central nervous system.

Authors:  Jane E Libbey; Robert S Fujinami
Journal:  Handb Clin Neurol       Date:  2014

10.  Suppression of measles virus expression by noncytolytic antibody in an immortalized macrophage cell line.

Authors:  M B Goldman; T A O'Bryan; D J Buckthal; L M Tetor; J N Goldman
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.